Yarchoan Mark, Louneva Natalia, Xie Sharon X, Swenson Frank J, Hu William, Soares Holly, Trojanowski John Q, Lee Virginia M-Y, Kling Mitchel A, Shaw Leslie M, Chen-Plotkin Alice, Wolk David A, Arnold Steven E
Department of Internal Medicine, University of Pennsylvania, Philadelphia, PA, United States.
J Neurol Sci. 2013 Oct 15;333(1-2):9-12. doi: 10.1016/j.jns.2013.05.028. Epub 2013 Aug 23.
C-reactive protein (CRP) participates in the systemic response to inflammation. Previous studies report inconsistent findings regarding the relationship between plasma CRP and Alzheimer's disease (AD). We measured plasma CRP in 203 subjects with AD, 58 subjects with mild cognitive impairment (MCI) and 117 normal aging subjects and administered annual Mini-Mental State Examinations (MMSE) during a 3-year follow-up period to investigate CRP's relationship with diagnosis and progression of cognitive decline. Adjusted for age, sex, and education, subjects with AD had significantly lower levels of plasma CRP than subjects with MCI and normal aging. However, there was no significant association between plasma CRP at baseline and subsequent cognitive decline as assessed by longitudinal changes in MMSE score. Our results support previous reports of reduced levels of plasma CRP in AD and indicate its potential utility as a biomarker for the diagnosis of AD.
C反应蛋白（CRP）参与机体对炎症的反应。既往研究关于血浆CRP与阿尔茨海默病（AD）之间的关系报道结果不一。我们测量了203例AD患者、58例轻度认知障碍（MCI）患者和117例正常老龄受试者的血浆CRP，并在3年随访期内每年进行简易精神状态检查（MMSE），以研究CRP与认知功能下降的诊断及进展之间的关系。校正年龄、性别和教育程度后，AD患者的血浆CRP水平显著低于MCI患者和正常老龄受试者。然而，根据MMSE评分的纵向变化评估，基线时的血浆CRP水平与随后的认知功能下降之间无显著关联。我们的结果支持既往关于AD患者血浆CRP水平降低的报道，并表明其作为AD诊断生物标志物的潜在效用。
